A Phase 4 interventional study of Colchicine Pill and Placebo in Colchicine Adverse Reaction and Atrial Fibrillation New Onset, sponsored by Bakulev Scientific Center of Cardiovascular Surgery. Completed at 2 sites in Russian Federation. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-20.
Sponsored by Bakulev Scientific Center of Cardiovascular Surgery · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing colchicine in Atrial Fibrillation — 4 open to participants now, 5 under way, 3 of them phase 3. Colchicine · Atrial Fibrillation.
Among the 22 studies testing colchicine in Atrial Fibrillation, this one is the 8th largest by enrollment, is one of 3 that started in 2019, is one of 4 in phase 4, and was the 12th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →4 of the 22 studies testing colchicine in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:
Ayesha Ather · Sites in United States
Ages 18–99
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
Elsan · Sites in France
Ages 18+
By country, each count listing its studies:
Colchicine: first FDA approval 1961 (COLBENEMID), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 14 · Phase 4 4
First in 2012; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 267 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 236 across the 22 interventional studies. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 22 have an industry lead sponsor. The 10 most frequent:
Bakulev Scientific Center of Cardiovascular Surgery is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Bakulev Scientific Center of Cardiovascular Surgery has 5 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
3 of the studies testing colchicine in Atrial Fibrillation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05890664Phase 3University Hospital, Basel, SwitzerlandColchicine After Electrocardioversion for Atrial Fibrillation | 2027-03 |
| NCT07287345Ayesha AtherColchicine's Effect on Inflammatory Markers | 2026-12-30 |
| NCT06765356Vivek ReddyPragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias | 2027-03-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies testing colchicine in Atrial Fibrillation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Postoperative atrial fibrillation (POAF) is a major complication of cardiac surgery, which could lead to high morbidity and mortality, increase duration of hospital stay and increase the cost of treatment. Colchicine possesses both anti-inflammatory and sympatholytic properties, so it has been studied to prevent POAF. The ACC/AHA guidelines for colchicine contain a class IIB recommendation, but the ESC guidelines do not recommend this drug. More researches are needed to focus on reducing of side effects by optimizing the colchicine regimen to reduce the incidence of gastrointestinal side effects. It is believed that further research is needed to investigate the efficacy and safety of colchicine in these conditions.
This research is aimed to study the effectiveness of short-term administration of the drug.
Postoperative atrial fibrillation (POAF) is a major complication of cardiac surgery, which could lead to high morbidity and mortality, increase duration of hospital stay and increase the cost of treatment. Postoperative AF is considered as a multifactorial phenomenon. Its pathogenesis is characterized by inflammation, oxidative stress and autonomic dysfunction. Several predisposing factors lead to the development of POAF, including pre -, intra-and postoperative factors. The main of them are age, previous history of major cardiovascular risk factors and ischemic reperfusion injury during surgery. Treatment of POAF involves drugs to control the frequency of rhythm in hemodynamically stable patients and other treatment regimens usually used for the treatment of AF. Intraoperative administration of beta-blockers and some antiarrhythmic drugs is recommended by international clinical guidelines. In addition, previous treatment consisting of the use of colchicine, magnesium sulfate, statins and antioxidants have reduced the incidence of postoperative AF. However, the results of large-scale randomized trials have observed the development of undesirable adverse reactions.
Despite these recommendations, the question of the correct regimen for prevention of POAF remains controversial. Colchicine possesses both anti-inflammatory and sympatholytic properties, so it has been studied to prevent POAF. The ACC/AHA guidelines for colchicine contain a class IIB recommendation, but the ESC guidelines do not recommend this drug.
Two studies sequentially COPPS-1 and COPPS-2 evaluated the effect of colchicine on the incidence of POAF after open heart surgery (COPPS-1) and the development of postcardiotomy syndrome (COPPS-2). In COPPS-1, patients (n=336) were treated with colchicine from the third day after surgery for a month and showed a significant decrease of POAF after heart surgery over the entire follow-up period. 360 patients were evaluated in the COPPS-2 study. The incidence of POAF between the colchicine and placebo groups was comparable, although colchicine significantly reduced postpericardiotomy syndrome. The main limitation of the COPSS-2 study was the high rate of cessation of intervention (20% of participants), which had a significant impact on the outcome of the trial.
Based on the latest meta-analysis of the colchicine effect on POAF after heart surgery, it was found that it still reduces POAF compared with control (HR = 0.69, 95% IM 0.57-0.84, p = 0.0002) and the duration of hospital stay was reduced by 1.2 days (95% IM -1.89 to -0.44, p = 0.002); however, the frequency of adverse gastrointestinal events increased significantly (HR = 2.52, 95% IM 1.62-3.93, p \< 0.0001). Despite the high level of side effects, a significant reduction of POAF outweighs the balance in the favor of its use. However, more researches are needed to focus on reducing of side effects by optimizing the colchicine regimen to reduce the incidence of gastrointestinal side effects. It is believed that further research is needed to investigate the efficacy and safety of colchicine in these conditions.
This research is aimed to study the effectiveness of short-term administration of the drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult patients awaiting elective cardiac surgery (CABG and/or AVR (aortic valve replacement), who are willing and able to give for participation in the study and who are in sinus rhythm and not taking any antiarrhythmic medication, except beta-adrenergic blocking agents, at the time before surgery.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Colchicine 1 mg day (COLCHICINA LIRCA ® ACARPIA Farmaceutici S.r.l.)
Drug: Colchicine Pill
Sugar pill
Drug: Placebo
Colchicine at a dose of 1 mg a day before surgery, 2, 3, 4, 5 days after surgery.
Also known as: group C
Placebo started a day before surgery, 2, 3, 4, 5 days after surgery.
Also known as: group P
Number of participants with postoperative atrial fibrillation.
POAF detected on continuous ECG monitoring.
Time frame: Monitoring is carried out immediately after surgery and will be continued until the end of the 7th postoperative day.
Number of participants with lethal and non-lethal events.
The main nosocomial lethal and non-lethal events (death, stroke, myocardial infarction, heart failure).
Time frame: Participants will be followed for the duration of the postoperative period up to the day of initial discharge from the hospital, an expected average of 7 days.
Fluid in the pericardium.
Fluid in the pericardium evaluated by echocardiography.
Time frame: Diagnostics will be carried out on the 3rd and 5th day after surgery.
Fluid in the pleura.
Fluid in the pleura evaluated by echocardiography.
Time frame: Diagnostics will be carried out on the 3rd and 5th day after surgery.
Acute kidney damage (according to the dynamics of creatinine clearance).
Dynamics of creatinine clearance.
Time frame: Diagnostics will be carried out a day before surgery and on the 3rd and 5th day after surgery.
Inflammation in blood plasma.
Dynamics of biomarker of inflammation in blood plasma (neutrophils).
Time frame: Diagnostics will be carried out a day before surgery and on the 3rd and 5th day after surgery.
Liver damage
Dynamics of biomarkers of liver damage (aspartate aminotransferase, alanine aminotransferase).
Time frame: Diagnostics will be carried out a day before surgery and on the 3rd and 5th day after surgery.
Plan to share: Yes — The datasets analyzed during the current study are publicly available. The data is available in the general repository "Open Science Framework" at the link
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: until 2045
Access criteria: open access
Data sharing details ↗ · doi.org
Ran from Dec 2019 to primary completion in Aug 2022, 31 months.
Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's 31 months is below that.
Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Colchicine
Bakulev Scientific Center of Cardiovascular Surgery